Pulse Biosciences (NASDAQ:PLSE) Director Robert Duggan Purchases 660,233 Shares

by · The Cerbat Gem

Pulse Biosciences, Inc (NASDAQ:PLSE – Get Free Report) Director Robert Duggan bought 660,233 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average price of $19.69 per share, for a total transaction of $12,999,987.77. Following the completion of the purchase, the director owned 48,211,433 shares in the company, valued at $949,283,115.77. The trade was a 1.39% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Pulse Biosciences Price Performance

Pulse Biosciences stock remained flat at $19.08 during mid-day trading on Monday. 953,297 shares of the company’s stock were exchanged, compared to its average volume of 318,598. Pulse Biosciences, Inc has a twelve month low of $12.56 and a twelve month high of $26.30. The company has a fifty day moving average price of $20.85 and a two-hundred day moving average price of $17.59. The firm has a market capitalization of $1.30 billion, a P/E ratio of -17.35 and a beta of 1.63.

Pulse Biosciences (NASDAQ:PLSE – Get Free Report) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.05. The firm had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.25 million. Research analysts anticipate that Pulse Biosciences, Inc will post -1.29 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Mizuho set a $30.00 price objective on Pulse Biosciences in a research note on Friday, February 6th. Wall Street Zen upgraded Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, February 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Tuesday, April 21st. Finally, Oppenheimer reiterated an “outperform” rating and set a $30.00 price objective on shares of Pulse Biosciences in a research note on Friday, February 20th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $30.00.

View Our Latest Stock Report on PLSE

Hedge Funds Weigh In On Pulse Biosciences

Institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets grew its holdings in Pulse Biosciences by 63.6% in the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after purchasing an additional 680 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of Pulse Biosciences by 275.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after buying an additional 2,156 shares in the last quarter. Russell Investments Group Ltd. grew its stake in Pulse Biosciences by 13.8% in the 4th quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock valued at $70,000 after acquiring an additional 619 shares during the period. KLP Kapitalforvaltning AS increased its holdings in Pulse Biosciences by 136.0% in the 3rd quarter. KLP Kapitalforvaltning AS now owns 5,900 shares of the company’s stock worth $104,000 after acquiring an additional 3,400 shares in the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new position in Pulse Biosciences during the second quarter worth $158,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

(Get Free Report)

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.

Read More